Skip to main content

Revolutionizing Peptide Purification: A Blueprint for MCSGP Process Validation

Revolutionizing Peptide Purification: A Blueprint for MCSGP Process Validation

The shift from batch to continuous manufacturing is a requirement in many biopharma applications, but regulatory compliance, specifically Process Validation, remains a hurdle for many.

A recent milestone study by Ralf Eisenhuth (Bachem AG) and Thomas Müller-Späth (YMC ChromaCon) provides the first-ever comprehensive framework for the Process Characterization (PC) and Process Performance Qualification (PPQ) of MCSGP (Multicolumn Countercurrent Solvent Gradient Purification) with AutoPeak® technology.

Using the synthetic peptide Bivalirudin as a test case, the authors demonstrate how to transition this continuous technology into a fully regulated, commercial-scale environment.

Highlights of this article include:

  • Comprehensive Framework for PC and PPQ of MCSGP
  • Defining Criticality: Out of 34 identified process parameters, only the gradient slope was classified as a Critical Process Parameter (CPP), requiring tighter control limits.
  • Process Analytical Technology (PAT) in Action: The study highlights AutoPeak® technology as a critical PAT. It uses real-time UV triggers to adjust for peak shifts, ensuring consistent internal recycling and product collection without manual intervention.
  • Efficiency Gains: Compared to traditional batch chromatography with extensive side-cut recycling, the MCSGP process achieved:
    • Yield Increase: From 57% to 62% (gross-to-gross).
    • Process Mass Intensity Reduction: PMI dropped from ~5200 to 1400 kg/kg—a massive win for sustainability.
    • Simplified QC: In-process controls (IPCs) were slashed from 81 per kg to just 3.2 per kg.
    • Robust Control: Supported by online measurements, MCSGP is capable of running uninterrupted over several days.

Why This Matters:

This work provides, for the first time, a stringent pathway to form the foundation of the Process Validation lifecycle of therapeutics produced via continuous chromatography. It proves that MCSGP with AutoPeak® technology isn’t just a lab-scale efficiency tool; it is a robust, validated, and highly sustainable solution for commercial peptide and oligonucleotide manufacturing.

Posted on March 24, 2026.

Related Posts

September 4, 2026

YMC America Brings U.S.-Supplied ASME U-Stamped DAC Columns to Pharmaceutical Manufacturers

YMC America will be the First U.S.-Based Supplier of ASME U-Stamped DAC Columns. The company’s DAC columns support pharmaceutical and biopharmaceutical customers from process development through commercial production. Systems are used in laboratory, pilot, and production-scale chromatography applications, including purification processes for peptides, oligonucleotides, and small-molecule APIs.

September 10, 2026

Analytical Technologies for Therapeutic Peptides

Therapeutic peptides are an emerging class of active pharmaceutical ingredients that, together with other classes of bioproducts, have been attracting considerable attention due to their unique advantages. Their structure is based on well-defined amino acid sequences that may or may not contain structural modifications, resulting in molecules that generally range from 500 to 5000 Da. Currently, many examples can be used as medicines related to hormones, growth factors, neurotransmitters, among others.

September 9, 2026

Tecnologias Analíticas para Peptídeos Terapêuticos- Portuguese

Os peptídeos terapêuticos são uma classe emergente de insumos farmacêuticos ativos que, juntamente com outras classes de bioprodutos, vêm despertando grande interesse devido às suas vantagens únicas.

Designed and developed by